UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d)
of The Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported): June 24, 2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-39070
|
|
32-0463781
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
1000 Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(847)
388-0349
Registrant’s telephone number,
including area code
N/A
(Former name or former address, if
changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each
class
|
|
Trading
Symbol(s)
|
|
Name of each
exchange on which registered
|
|
Common Stock,
$0.001 par value
|
|
MNPR
|
|
The Nasdaq Stock
Market LLC
(Nasdaq Capital
Market)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of
the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☒
Item
7.01 Regulation
FD Disclosure
On June
24, 2021, Monopar Therapeutics Inc. issued a press release
announcing a presentation on oropharyngeal cancer (OPC) patient
population analysis of the Phase 2 Validive® (clonidine HCl
MBT) trial for the prevention of chemoradiotherapy-induced severe
oral mucositis in head and neck cancer at the Multinational
Association of Supportive Care in Cancer and International Society
of Oral Oncology (MASCC/ISOO) 2021 annual meeting.
The
press release is furnished as Exhibit 99.1 and the supplemental
slides are furnished as Exhibit 99.2 to this report and
incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
Press Release
Dated June 24, 2021
|
|
|
|
|
|
|
|
Supplemental
slides provided in connection with Monopar Therapeutics
Inc.’s presentation at the MASCC/ISOO 2021 annual
meeting.
|
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Monopar Therapeutics Inc.
|
|
|
|
|
|
|
|
Date: June 24, 2021
|
By:
|
/s/ Kim R. Tsuchimoto
|
|
|
|
|
Name: Kim R. Tsuchimoto
|
|
|
|
|
Title: Chief Financial Officer, Secretary and
Treasurer
|
|